Skip to main content

Advertisement

SpringerLink
Log in

Inflammatory Demyelinating Neuropathies

  • Neuromuscular Disorders
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

The primary goal of therapy in patients with the Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is improved strength and functional ability. Improvement in pain, sensory loss, gait disorder, and autonomic instability are other goals of therapy. Patients with very mild symptoms that do not interfere with activities of daily living can be observed for deterioration without treatment. For GBS, standard care includes plasma exchange (PE) or human immune globulin (HIG), both of which have similar efficacy. Supportive care in the intensive care unit may be needed for those patients with severe bulbar or respiratory weakness. We treat most patients with PE, usually performing an exchange every other day for a total of five exchanges. We use HIG in children, if there are antiglycolipid antibodies (eg, anti-GM1 or anti-GQ1b) or if there is a contraindication to PE, such as hemodynamic instability; severe renal, hepatic, or cardiac disease; or poor venous access. For CIDP, there are no guidelines concerning the initial choice of therapy. Corticosteroids, HIG, and PE have all been shown to be effective in prospective, randomized controlled trials, and comparison trials have shown equal efficacy among these three immunomodulating therapies. The choice of therapy depends on several factors including disease severity, concomitant illnesses, side-effect profile, potential drug interactions, venous access, age-related risks, and cost of treatment. In patients with moderate to severe symptoms, treatment with corticosteroids or HIG should be used. We usually use high-dose, intermittent methylprednisolone as the initial drug of choice. We believe intermittent corticosteroids are better than HIG because of their good safety profile, low cost, ease of administration (can be given intravenously or by mouth), and proven efficacy. If there is a major contraindication to corticosteroids, then HIG is offered. PE is less well tolerated and is primarily used as a third choice and only for a few weeks to months to induce initial improvement. Once symptoms are improving, the dose of corticosteroids or HIG should be tapered with the goal of eventual discontinuation depending on patient response. Patients who do not respond to initial therapy, experience adverse effects from the initial immunomodulating agent, or require chronic treatment can be treated with another first-line agent or one of several second-line agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ropper AH, Wijdicks EFM, Truax BT: Guillain-Barré Syndrome. Philadelphia: Davis; 1991.

    Google Scholar 

  2. Hahn AF, Hartung H-P, Dyck PJ: Chronic inflammatory demyelinating polyradiculoneuropathy. In Peripheral neuropathy, edn 4th. By Dyck PJ, Thomas PK. Philadelphia: Elsevier Saunders; 2005:2221–2253.

    Google Scholar 

  3. Kuwabara S, Mori M, Ogawara K, et al.: Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001, 24:54–58.

    Article  PubMed  CAS  Google Scholar 

  4. Yuki N, Ang CE, Koga M, et al.: Clinical features and response to treatment in Guillain-Barré syndrome associates with antibodies to GM1b ganglioside. Ann Neurol 2000, 47:314–321.

    Article  PubMed  CAS  Google Scholar 

  5. Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997, 48:321–328.

    PubMed  CAS  Google Scholar 

  6. Simmons Z, Albers JW, Bromberg MB, Feldman EL: Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995, 118:359–368.

    Article  PubMed  Google Scholar 

  7. Dyck PJ, Low PA, Windebank AJ, et al.: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991, 325:1482–1486.

    Article  PubMed  CAS  Google Scholar 

  8. Pestronk A, Chuquilin M, Choksi R: Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside. J Neurol Neurosurg Psychiatry 2010, 81:726–730.

    Article  PubMed  Google Scholar 

  9. Greenwood RJ, Newsom-Davis J, Hughes RAC, et al.: Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984, 1:877–879.

    Article  PubMed  CAS  Google Scholar 

  10. The Guillain-Barré Syndrome Study Group: Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985, 35:1096–1104.

    Google Scholar 

  11. Osterman PO, Fagius J, Lundemo G, et al.: Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984, 2:1296–1299.

    Article  PubMed  CAS  Google Scholar 

  12. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome: Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987, 22:753–761.

    Article  Google Scholar 

  13. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome: Appropriate number of plasma exchanges in Guillain-Barré Syndrome. Ann Neurol 1997, 41:298–306.

    Article  Google Scholar 

  14. van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992, 326:1123–1129.

    Article  PubMed  Google Scholar 

  15. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K: Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996, 46:100–103.

    PubMed  CAS  Google Scholar 

  16. PSGBS-Study Group: Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997, 349:225–230.

    Article  Google Scholar 

  17. Dyck PJ, O’Brien PC, Oviatt KF, et al.: Prednisone improves chronic inflammatory polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136–141.

    Article  PubMed  CAS  Google Scholar 

  18. Molenaar DSM, van Doorn PA, Vermeulen M: Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997, 62:388–390.

    Article  PubMed  CAS  Google Scholar 

  19. Lopate G, Pestronk A, Al-Lozi M: Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005, 62:249–254.

    Article  PubMed  Google Scholar 

  20. Muley SA, Kelkar P, Parry GJ: Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 2008, 65:1460–1464.

    Article  PubMed  Google Scholar 

  21. van Schaik IN, Eftimov F, van Doorn PA, et al.: Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9:245–253.

    Article  PubMed  Google Scholar 

  22. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993, 56:36–39.

    Article  PubMed  CAS  Google Scholar 

  23. Dyck PJ, Litchy WJ, Kratz KM, et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994, 36:838–845.

    Article  PubMed  CAS  Google Scholar 

  24. Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996, 119:1067–1077.

    Article  PubMed  Google Scholar 

  25. Thompson N, Choudhary P, Hughes RAC, Quinlivan RM: A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996, 243:280–285.

    Article  PubMed  CAS  Google Scholar 

  26. Mendell JR, Barohn RJ, Freimer ML, et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56:445–449.

    PubMed  CAS  Google Scholar 

  27. Hughes R, Bensa S, Willison HJ, et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195–201.

    Article  PubMed  CAS  Google Scholar 

  28. Hughes RA, Donofrio P, Bril V, ICE Study Group, et al.: Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE Study): a randomised placebo-controlled trial. Lancet Neurol 2008, 7:136–144.

    Article  PubMed  CAS  Google Scholar 

  29. Hahn AF, Bolton CF, Pillay N, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. A double blind, sham-controlled, crossover study. Brain 1996, 119:1055–1066.

    Article  PubMed  Google Scholar 

  30. Dyck PJ, Daube J, O’Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461–465.

    Article  PubMed  CAS  Google Scholar 

  31. Korinthenberg R, Schessl J, Kirschner J, Monting JS: Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005, 116:8–14.

    Article  PubMed  Google Scholar 

  32. Dalakas MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004, 102:177–193.

    Article  PubMed  CAS  Google Scholar 

  33. Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson DR: Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis. J Clin Apher 1999, 14:107–113.

    Article  PubMed  CAS  Google Scholar 

  34. Parry GJ, Steinberg JS (eds.): Guillain-Barré syndrome: from diagnosis to recovery. Saint Paul: AAN; 2007:109–146.

    Google Scholar 

  35. Dyck PJ, O’Brien P, Swanson C, et al.: Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1985, 35:1173–1176.

    PubMed  CAS  Google Scholar 

  36. Dalakas MC, Engel WK: Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981, 9:134–145.

    Article  PubMed  Google Scholar 

  37. Barnett MH, Pollard JD, Davies L, et al.: Cyclosporine A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998, 21:454–460.

    Article  PubMed  CAS  Google Scholar 

  38. Mahattanakul W, Crawford TO, Griffin JW, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996, 60:185–187.

    Article  PubMed  CAS  Google Scholar 

  39. Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715–717.

    PubMed  CAS  Google Scholar 

  40. Bedi G, Brown A, Tong T, Sharma R: Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry 2010, 81:634–636.

    Article  PubMed  Google Scholar 

  41. Good JL, Chehrenama M, Mayer RF, et al.: Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 51:1735–1738.

    PubMed  CAS  Google Scholar 

  42. Gladstone DE, Prestrud AA, Brannagan 3rd TH: High dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerve Syst 2005, 10:11–16.

    Article  CAS  Google Scholar 

  43. Lee DH, Linker RA, Paulus W, et al.: Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008, 37:406–409.

    Article  PubMed  CAS  Google Scholar 

  44. Magy L: Subcutaneous injections of polyvalent immunoglobulins as a maintenance therapy for intravenous immunoglobulin-responsive patients with chronic inflammatory demyelinating polyneuropathy [abstract]. J Peripher Nerv Syst 2008, 13:176.

    Google Scholar 

  45. Benedetti L, Briani C, Franciotta D, et al.: Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy; a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2010 Jul 16 (Epub ahead of print). This is the largest series of refractory CIDP patients to receive rituximab, many with concomitant hematologic disease (paraproteinemia or lymphoma). Of 13 patients, 9 responded and no major adverse events were noted.

  46. Marsh EA, Hirst CL, Llewelyn JG, et al.: Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010, 257:913–919.

    Article  PubMed  CAS  Google Scholar 

  47. Mahdi-Rogers M, Kazmi M, Ferner R, et al.: Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Periph Nerve Syst 2009, 14:118–124.

    Article  Google Scholar 

  48. Oyama Y, Sufit R, Loh Y, et al.: Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology 2007, 69:1802–1803.

    Article  PubMed  CAS  Google Scholar 

  49. Remenyi P, Masszi T, Borbenyi Z, et al.: CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol 2007, 14:e1–e2.

    Article  PubMed  CAS  Google Scholar 

  50. Gürses N, Uysal S, Çetinkaya F, Íslek Í, Kalayci AG: Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995, 27:241–243.

    Article  PubMed  Google Scholar 

  51. Wang R, Feng A, Sun W, Wen Z: Intravenous immunoglobulin in children with Guillain-Barré syndrome. J Appl Clin Ped 2001, 16:223–224.

    Google Scholar 

  52. Nevo Y, Pestronk A, Kornberg AJ, et al.: Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 1996, 47:98–102.

    PubMed  CAS  Google Scholar 

  53. Connolly AM: Chronic inflammatory demyelinating polyneuropathy in childhood. Pediatr Neurol 2001, 24:177–182.

    Article  PubMed  CAS  Google Scholar 

  54. Ryan MM, Grattan-Smith PJ, Procopis PG, Morgan G, Ouvrier RA: Childhood chronic inflammatory demyelinating polyneuropathy: clinical course long-term outcome. Neuromuscul Disord 2000, 10:398–406.

    Article  PubMed  CAS  Google Scholar 

  55. Hattori N, Ichimura M, Aoki S, et al.: Clinicopathological features of chronic inflammatory demyelinating polyradiculoneuropathy in childhood. J Neurol Sci 1998, 154:66–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Conflicts of Interest: G. Lopate: none; A. Pestronk: Honoraria, patents, and royalties from Athena, and stock or stock options from Johnson & Johnson.

Author information

Authors and Affiliations

  1. Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8111, St. Louis, MO, 63110, USA

    Glenn Lopate MD & Alan Pestronk MD

Authors
  1. Glenn Lopate MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Pestronk MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glenn Lopate MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lopate, G., Pestronk, A. Inflammatory Demyelinating Neuropathies. Curr Treat Options Neurol 13, 131–142 (2011). https://doi.org/10.1007/s11940-011-0114-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-011-0114-0

Keywords

Search

Navigation